A Look at Advancements in Thyroid Cancer Research &… : Oncology Times
An abstract is unavailable.
An abstract is unavailable.
Daratumumab plus VRd improved MRD responses and progression-free survival in transplant-ineligible or -deferred newly diagnosed multiple myeloma.
Revumenib demonstrated meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia.
Blinatumomab plus chemotherapy significantly improved 3-year DFS rates vs chemotherapy alone in pediatric patients with standard-risk pediatric B-ALL.
Eunice S. Wang, MD, on ziftomenib plus intensive induction in newly diagnosed, NPM1-mutated or KMT2A-rearranged acute myeloid leukemia.
Sacituzumab tirumotecan has received breakthrough therapy designation from the FDA for use in select patients with EGFR+ non–small cell lung cancer.
Es una de las más extensas de España con entrada submarina
The Northwestern University Nervous System Tumor Bank provides scientists with high-quality, patient-derived biospecimens to support preclinical and translational neuro-oncology research.
Disitamab vedotin showed early activity in HER2-expressing metastatic breast cancer with abnormal PAM pathway activation.
Research by Fred Hutch Cancer Center genetic epidemiologist Burcu Darst, PhD, and scientists from the Canary Prostate Active Surveillance Study (PASS), suggests that a patient’s…
ment. Case reports provide most of the current literature, and thus common injury mechanisms, clinical presentation, and ideal treatment time frame and modality are still…